Quantcast
Last updated on April 20, 2014 at 7:40 EDT

Latest kidney transplant Stories

2013-09-04 08:31:46

Veloxis Introduces Envarsus® as Trade Name for LCP-Tacro(TM) HORSHOLM, Denmark, Sept. 4, 2013 /PRNewswire/ -- Veloxis Pharmaceuticals A/S (OMX: VELO) today announced that data from the 3002, randomized, double-blind, double-dummy, Phase III study in 543 de novo kidney transplant patients will be presented at the European Society for Organ Transplantation as a late-breaker oral presentation at 8:30 a.m. CEST, Sept. 9, in Vienna. Veloxis' once-daily LCP-Tacro(TM), now with the trade...

2013-08-23 10:38:07

NIH-funded study provides more evidence supporting development of noninvasive tests Levels of a protein in the urine of kidney transplant recipients can distinguish those at low risk of developing kidney injury from those at high risk, a study suggests. The results also suggest that low levels of this protein, called CXCL9, can rule out rejection as a cause of kidney injury. The study appears online Aug. 22 in the American Journal of Transplantation. The work was funded by the National...

2013-08-22 08:27:33

NORTHBROOK, Ill., Aug. 22, 2013 /PRNewswire/ -- Astellas Pharma US, Inc. ("Astellas"), a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503), announced today that ASTAGRAF XL(TM) (tacrolimus extended-release capsules) for the prophylaxis of organ rejection in patients receiving a kidney transplant used with mycophenolate mofetil (MMF) and corticosteroids, with or without basiliximab induction, is now available in U.S. pharmacies. "The availability of ASTAGRAF XL marks a...

2013-08-20 17:14:40

Full-time workers more likely to get transplants People in end-stage kidney failure in need of a kidney transplant are much less likely to be placed on a waiting list for a new kidney or to actually receive a new kidney once on the list if they are unemployed or work part time, according to new collaborative research from the University of New Hampshire. "There is a strong negative association between a patient's unemployment and the likelihood of being placed on a waiting list for a...

2013-08-06 23:21:46

Camden Couple Participates in a Donor Chain Involving 20 People and 10 Hospitals from Coast To Coast CAMDEN, NJ (PRWEB) August 06, 2013 Betty and Orlando Gonzalez, of Camden, have shared many special years together. So when Orlando, 50, needed a kidney transplant, his wife, Betty, stepped up to donate. Unfortunately, Orlando and Betty’s blood types did not match. So the staff at Our Lady of Lourdes Medical Center—the only organ transplant facility in South Jersey—entered them into a...

2013-07-30 11:06:37

Patients who received their first kidney transplant at ages 14 to 16 years appear to be at increased risk for transplant failure, with black adolescents having a disproportionately higher risk of graft failure, according to a report published by JAMA Internal Medicine, a JAMA Network publication. Existing medical literature does not adequately describe the risks of graft failure among kidney transplant recipients by age. Organ losses by adolescents are partly due to physiologic or...

2013-07-19 20:20:54

NORTHBROOK, Ill., July 19, 2013 /PRNewswire/ -- Astellas Pharma US, Inc. ("Astellas"), a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503), announced today that the U.S. Food and Drug Administration (FDA) has approved ASTAGRAF XL(TM) (tacrolimus extended-release capsules) for the prophylaxis of organ rejection in patients receiving a kidney transplant with mycophenolate mofetil (MMF) and corticosteroids, with or without basiliximab induction. "Each transplant...

2013-06-27 12:28:21

- LCP-Tacro(TM), once-daily, demonstrated non-inferiority to Prograf®, twice-daily, based on the composite endpoint of treatment failure at one year (LCP-Tacro(TM) 18.3%, Prograf® 19.6%) HORSHOLM, Denmark, June 27, 2013 /PRNewswire/ -- Veloxis Pharmaceuticals A/S (OMX: VELO) today announced LCP-Tacro(TM) successfully demonstrated non-inferiority compared to tacrolimus (Prograf(®); Astellas Pharma) in its Phase III clinical trial, Study 3002. The Phase III randomized,...

2013-04-29 08:27:28

HORSHOLM, Denmark, April 29, 2013 /PRNewswire/ -- Veloxis Pharmaceuticals A/S (OMX: VELO) today announced that it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) seeking approval to market LCP-Tacro for the prevention of organ rejection in kidney transplant patients in the European Union. The MAA submission is based on the favorable results of the LCP-Tacro Phase III 3001 study in stable kidney transplant patients and data from an extensive...

2013-04-19 08:25:13

Multidisciplinary approach to transplant therapy gives chronic kidney disease sufferers "a new chance at life" - while currently serving more African-American patients per capita than any other program in the United States. DETROIT, April 19, 2013 /PRNewswire-USNewswire/ -- Christopher Brantley says he will never forget the moment when he realized that he was going to need dialysis for life if he didn't get a kidney transplant. (Photo:...